Skip to Content
Merck
CN

719927

Resomer® RG 756 S, Poly(D,L-lactide-co-glycolide)

ester terminated, lactide:glycolide 75:25, Mw 76,000-115,000

Synonym(s):

PLGA

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
MDL number:
UNSPSC Code:
12162002
NACRES:
NA.23
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Level

form

amorphous

feed ratio

lactide:glycolide 75:25

mol wt

Mw 76,000-115,000

degradation timeframe

<6 months

viscosity

0.71-1.0 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 49-55 °C

storage temp.

2-8°C

SMILES string

O2C(C(=O)OC(C2=O)C)C.O1CC(=O)OCC1=O

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

Application

Poly (lactic-co-glycolic acid) 75:25 copolymer may be used to design a controlled drug delivery implant.
Controlled release

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Articles

商业生物材料已停滞不前超过30年的时间,因为很少有材料能够成功地从实验台过渡到临床使用。合成型脂族聚酯因其悠久的历史和获得美国食品药品监督管理局(FDA)批准的记录,一直在可吸收生物材料领域占据主导地位。

In the past two decades, tissue engineering and regenerative medicine have become important interdisciplinary fields that span biology, chemistry, engineering, and medicine.

Innovations in polymer technology have had a significant impact on the advancement of novel drug delivery systems.

View All Articles

An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation.
Kamali H, et al.
Journal of drug delivery science and technology, 47, 95-105 (2018)
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Shu-Chun Chuang et al.
Parasites & vectors, 6, 34-34 (2013-02-13)
Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or



Global Trade Item Number

SKUGTIN
719927-1G04061832855493
719927-5G04061835563715